Groundbreaking approach offers ray of hope for ovarian cancer patients
In a twist of fate, 24-year-old Tora Murphy’s globetrotting adventure took an unexpected turn when her health journey began. What started as a quest to explore the world swiftly turned into a battle against ovarian cancer, a disease she never imagined would become a part of her reality.
"I was looking pregnant, like I looked about six months pregnant," Murphy recounted to 9News. "They basically told me that it was stage three cancer and I was just in shock."
Her whirlwind journey abruptly halted as she returned to Brisbane to confront the daunting reality of her diagnosis. Ovarian cancer, a silent killer, had taken root in her body, presenting as a formidable 18cm tumour. Murphy’s resilience was put to the test as she underwent surgery to remove the tumour and ultimately a full hysterectomy.
"I didn't even know that people like me could get cancer," she expressed, echoing the disbelief many young women feel upon receiving such a diagnosis.
Ovarian cancer remains a formidable adversary, claiming the lives of 1000 Australian women each year, with a five-year survival rate hovering at a concerning 49 percent. For Murphy and countless others, the fear of recurrence looms large, casting a shadow over their lives.
However, amidst the darkness, there shines a glimmer of hope. Pioneering research led by Mater Research scientists is illuminating new pathways in the fight against ovarian cancer. Their focus? Dendritic cells, a key component of the immune system.
"We think that by focusing on that cell type in particular, that we'll be able to actually make a vaccine to help fight that disease and to eventually help prevent recurrence," explained Professor Kristen Radford from Mater Research.
This groundbreaking approach offers a ray of hope for individuals like Murphy, offering the possibility of a future where ovarian cancer is not only treatable but preventable. The development of a vaccine holds the promise of transforming the landscape of ovarian cancer treatment and prevention.
Fuelling this hope is the unwavering support of communities and organisations dedicated to combating ovarian cancer. The Ovarian Cancer Research Foundation, through its tireless fundraising efforts, has allocated $670,000 to support the vaccine development, part of a larger $2.4 million grant initiative.
"These funds have been raised by our community, so that's people out there walking, running, baking, shaving their heads," says Georgie Herbert from the Ovarian Cancer Research Foundation.
For Murphy, the outpouring of support from her partner, friends and the broader community serves as a symbol of strength during her darkest hours. As her loved ones prepare to walk 100km this coming May to raise funds in her honour, Murphy is buoyed by the knowledge that every step taken brings them closer to a future free from the grips of ovarian cancer.
"Their money goes to such a good place," she remarked, underscoring the impact of collective action in driving progress in ovarian cancer research and treatment.
As the fight against ovarian cancer continues, fuelled by groundbreaking research and unwavering community support, there is renewed optimism on the horizon for individuals like Tora Murphy and the thousands affected by this disease.
Images: Facebook